Skip to main content
. Author manuscript; available in PMC: 2008 Oct 26.
Published in final edited form as: J Am Soc Nephrol. 2005 Jan 12;16(3):703–711. doi: 10.1681/ASN.2004080649

Figure 1.

Figure 1

Profiles of systolic BP (SBP; A), body weight (BW; B), postprandial blood glucose (PPBG; C), and urinary protein excretion (UproteinV; D). OLETF rats develop hypertension, obesity, diabetes, and proteinuria. In these animals, temporary treatment with olmesartan, temocapril, a combination of these, or hydralazine at the prediabetic stage (4 to 11 wk of age) does not affect the development of hypertension, obesity, or high glucose levels later in life. However, the progression of proteinuria is markedly suppressed by temporary treatment with olmesartan, temocapril, or a combination of these but not by treatment with hydralazine.